Eupraxia Pharmaceuticals Raises $55 Million to Advance Eosinophilic Esophagitis Treatment
核心洞察
Eupraxia Pharmaceuticals (搜索) successfully priced a $55 million public offering to fund development of EP-104GI (搜索) for eosinophilic esophagitis (搜索) and other gastrointestinal conditions.
The company will use proceeds to complete Phase 2 trials and prepare for Phase 3 studies of EP-104GI (搜索), leveraging its proprietary Diffusphere (搜索) technology for targeted drug delivery.
Additional funding will support expansion into esophageal strictures and fibrostenotic Crohn's disease (搜索), addressing multiple areas of high unmet medical need.
Eupraxia Pharmaceuticals (搜索) Inc. (NASDAQ:EPRX) (TSX:EPRX) announced the successful pricing of a $55 million public offering on February 19, 2026, positioning the clinical-stage biotechnology company to advance its lead candidate EP-104GI (搜索) for eosinophilic esophagitis (搜索) and expand into additional gastrointestinal indications.
The offering consisted of 6,428,574 common shares priced at $7.00 per share and pre-funded warrants to purchase up to 1,428,571 common shares at $6.99999 per warrant. The company also granted underwriters a 30-day option to purchase up to an additional 1,178,571 common shares on the same terms.
Advancing EP-104GI Development
Eupraxia plans to use the net proceeds primarily for the continued advancement of EP-104GI (搜索) for eosinophilic esophagitis (搜索), including completion of ongoing preclinical studies and Phase 2 clinical trials. The funding will also support preparations for Phase 3 clinical trials, including related regulatory submissions and manufacturing activities, as well as commercial and market development activities to prepare for eventual product launch.
The company's proprietary Diffusphere (搜索) technology, a polymer-based micro-sphere platform, is designed to facilitate targeted drug delivery of both existing and novel drugs through locally delivered, extended-release formulations.
Expanding Gastrointestinal Pipeline
Beyond eosinophilic esophagitis (搜索), Eupraxia intends to use a portion of the proceeds to accelerate and expand clinical studies with EP-104GI (搜索) in multiple additional gastrointestinal indications, including esophageal strictures and fibrostenotic Crohn's disease (搜索). These conditions represent areas with significant unmet medical need where the company's controlled drug delivery technology could provide therapeutic advantages.
Additional funding will be allocated to research and development of other pipeline candidates, business development initiatives, and general corporate purposes including employee salaries, working capital, facility leases, administrative expenses, and capital expenditures. The company may also expand its intellectual property portfolio and strengthen corporate infrastructure to support future growth.
Financial Structure and Timeline
Cantor (搜索) and LifeSci Capital (搜索) served as joint book-running managers for the offering, with Bloom Burton (搜索) and Craig-Hallum acting as co-managers. The offering is expected to close on February 20, 2026, subject to customary closing conditions including listing approval on both the Toronto Stock Exchange and Nasdaq Capital Market.
Each pre-funded warrant entitles holders to acquire one common share at a nominal exercise price of C$0.00001 per share and will not expire until exercised in full. The offering was conducted under the company's existing Canadian short form base shelf prospectus dated February 5, 2024, and a U.S. registration statement on Form F-10 declared effective by the SEC on February 7, 2024.